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Ao the Editor: Large clinical trials have established the role of
lopidogrel in acute coronary syndrome and percutaneous coronary
ntervention (1–3). Light transmission aggregometry (LTA) is the
onventional method for measuring ex vivo platelet aggregation in
atients receiving clopidogrel. Most studies have used adenosine
iphosphate (ADP) as the agonist to trigger platelet aggregation.
owever, there is currently no consensus regarding the optimal
oncentration of ADP to use, thus making comparisons between
tudies difficult. Furthermore, LTA is routinely performed in
lood samples anticoagulated with citrate. Because extracellular
a2 plays a role in platelet aggregation (4), the calcium chelation
nduced by citrate may have an effect on the measurement of the
latelet inhibitory activity of clopidogrel. Therefore, the aims of
his study are: 1) to determine the optimal concentration of ADP
equired to consistently detect maximum platelet aggregation, and
) to evaluate whether the Ca2 chelation induced by citrate
verestimates platelet inhibition in patients on clopidogrel therapy.
The study population consisted of 34 patients with coronary artery
isease receiving aspirin and clopidogrel therapy. Therefore, no
aseline blood samples were obtained before the patients received
lopidogrel and aspirin. To allow for an individual’s full response to
lopidogrel, we included only patients who had been receiving
aintenance 75 mg therapy for5 days or had received a 300 mg or
00 mg loading dose at least 4 h before samples were taken. Patients
ere excluded if they met any of the following criteria: platelet count
150,000 or 450,000, hemoglobin 8 g/dl, or use of glycoprotein
Ib/IIIa inhibitors or warfarin in the past seven days. The Baylor
ollege of Medicine Institutional Review Board approved the study.
Blood samples were obtained by polypropylene syringes and
ollected from the arterial sheaths. Blood from each patient was
mmediately transferred into a tube containing 3.8% trisodium citrate
nd another tube containing the non-CA2 chelating anticoagulant
PACK (D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone)
nd then inverted gently. Platelet aggregation was assessed via
tandard LTA. Platelet aggregation was assessed using the PACKS-4
Helena Laboratories, Beaumont, Texas) four-channel light transmis-
ion aggregometer. Maximum extent of aggregation was calculated
fter the addition of different concentrations of ADP (1, 5, 10, and 20
M). Platelet aggregation was determined as the percent change in
ight transmission using platelet-poor plasma as the reference. No
latelet count adjustments were made.
Data are expressed as mean SD. Comparisons between citrate
nd PPACK at all four concentrations of ADP were analyzed by
aired t test. Comparisons among the four different concentrations
f ADP were accomplished using one-way analysis of variance. A
value of 0.05 was considered statistically significant.
Patient characteristics are displayed in Table 1. Platelet aggregation
n the citrate anticoagulated samples was 34.6 18.9% at 20 mol/l,
1.3  15.4% at 10 mol/l, 23.3  13.9% at 5 mol/l, and 5.6 
.5% at 1 mol/l ADP. In the PPACK anticoagulated tubes, platelet
ggregation was 45.4  21.1% at 20 mol/l, 40.6  19.2% at 10
mol/l, 32.8  15.2% at 5 mol/l, and 12.3  9.1% at 1 mol/l
DP (Fig. 1). There was no significant difference in percent of
latelet aggregation between 20 mol/l and 10 mol/l ADP in either

he citrate (p  0.4) or PPACK (p  0.3) samples. Significantly
reater platelet aggregation was seen in the PPACK samples as
ompared to citrate at all ADP concentrations (p 0.03 at 20mol/l,
 0.03 at 10 mol/l, p 0.01 at 5 mol/l, p 0.001 at 1 mol/l).
ll comparisons of platelet aggregation with different concentrations
f ADP in either the citrate group or the PPACK group (20 vs. 5
mol/l, 20 vs. 1 mol/l, 10 vs. 5 mol/l, 10 vs. 1 mol/l, and 5 vs.
mol/l) were significantly different except for those between 10
mol/l and 20 mol/l in both groups.
Even though ADP is the agonist most widely used to initiate
latelet aggregation for patients receiving clopidogrel, there is no
urrent standard regarding the optimal concentration of ADP or the
nticoagulant to use. Therefore, it is difficult to make valid compar-
sons of patients’ responses among different studies. This study
emonstrates that there is no statistical difference between the
ggregatory response at 10 mol/l and 20 mol/l ADP; therefore, it
ould be reasonable to use 10 mol/l as the standard concentration of
DP for testing.
To our knowledge, this study is the first to compare the
ifferential effects of citrate versus a non-Ca2 chelating antico-
gulant (PPACK) on platelet aggregation in patients receiving
able 1. Patient Characteristics
Study Population
(n  34)
emographics
Age (yrs), mean  SD 56.3  9
Men 19
isk Factors
Hypertension 32
Diabetes 9
History of MI 11
Dyslipidemia 16
Smoking (current) 12
rior Revascularization
Prior PCI 10
Prior CABG 2
edication
Aspirin 34
Clopidogrel 34
75 mg maintenance 28
300 or 600 mg LD 6
ACE inhibitor 26
Beta-blocker 32
Statin 32
Simvastatin 30
Atorvastatin 2
ematologic variables (mean  SD)
Platelet count (109/l) 260.9  71.6
Hemoglobin (g/dl) 13.3  1.9
LDL 110.4  41.2
HDL 33.8  10.5
Cr 1.1  0.4
CE  angiotensin-converting enzyme; CABG  coronary artery bypass graft; Cr
creatinine; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MI
myocardial infarction; PCI  percutaneous coronary intervention.
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465JACC Vol. 47, No. 2, 2006 Correspondence
January 17, 2006:464–71ual antiplatelet therapy of clopidogrel and aspirin. The results
emonstrate that citrate anticoagulated plasma undergoes mark-
dly less platelet aggregation, which was significant at all concen-
rations of ADP tested. This is noteworthy because studies have
uggested that there is a relationship between the degree of platelet
nhibition and major adverse clinical events (5).
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igure 1. Percent platelet aggregation in patients on clopidogrel using diff
ars) or PPACK (solid bars) as anticoagulant. *p  0.05.Removal of Iodine Contrast From Coronary Sin
xygen pressure (PO2) and partial carbon dioxide pressure (PCO2).
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concentrations of adenosine diphosphate (ADP) and either citrate (opendoi:10.1016/j.jacc.2005.10.032us in Swine During Coronary Angiographyo the Editor: The use of contrast during coronary angiogra-
hy (CA) in patients with renal disease is associated with a
ubstantial risk of renal failure (30% to 50%). Previous studies
ave shown that the amount of contrast used during CA
orrelates with contrast-induced nephropathy (CIN) (1,2).
espite preventive care, CIN occurs with high frequency and is
esponsible for adverse outcomes (1,2). Most of the cardiac
eins drain into the coronary sinus (CS). Anatomically, it
hould be possible to remove most of the contrast from the CS
uring CA using a catheter that can occlude the CS and remove
lood distal to the occlusion. Commercially available CS
atheters such as Heartport (Redwood City, California) (3) are
afely used in the CS for cardioplegia or during biventricular
acing. In this study, the Heartport catheter was used to remove
mixture of blood and contrast from the CS during CA of five
igs.
Five fasted swine were sedated with atropine (0.05 mg/kg,
ntramuscular injection) and ketamine (20 mg/kg, intramuscular
njection) and anesthetized with isoflurane. The ventilator settings
ere adjusted during the experiments to maintain normal partialThe left main coronary artery was accessed from the left carotid
rtery using an 8-F multipurpose catheter. Standard techniques
ere used with back flush of the contrast during CA under fluoros-
opy. Coronary angiography was performed after hand injection of 5
l of a non-ionic iodinated contrast material (Omnipaque-350,
mersham Health Inc., Princeton, New Jersey).
The CS was engaged by using a Heartport catheter (Ethicon
nc., Cornelia, Georgia) (Fig. 1) via the external jugular vein
nd 11-F sheath. Immediately after coronary injection, the
alloon at the tip of the catheter was inflated and CS blood was
ollected for 10 s (50 cc). Contrast injection and removal were
epeated three times. The occlusion of CS did not affect CA
nterpretation.
The amount of contrast in the collected blood from the CS was
uantified with high-performance liquid chromatography (samples
ere analyzed by Galbraith Laboratories, Knoxville, Tennessee)
nd a quantitative dual-energy technique developed in our labora-
ory. The University of California at Irvine Institutional Animal
are Committee approved this study.
We used a quantitative dual energy technique (4) for iodineerentass determination. All images were acquired using a conven-
